A clinician perspective on the treatment of chronic myeloid leukemia in the chronic phase

Tyrosine kinase inhibitors (TKIs) have vastly improved long-term outcomes for patients with chronic myeloid leukemia (CML). After imatinib (a first-generation TKI), second- and third-generation TKIs were developed. With five TKIs (imatinib, dasatinib, bosutinib, nilotinib, and ponatinib) targeting B...

Descripción completa

Detalles Bibliográficos
Autores principales: García-Gutiérrez, Valentin, Breccia, Massimo, Jabbour, Elias, Mauro, Michael, Cortes, Jorge E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9272596/
https://www.ncbi.nlm.nih.gov/pubmed/35818053
http://dx.doi.org/10.1186/s13045-022-01309-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9272596/
https://www.ncbi.nlm.nih.gov/pubmed/35818053
http://dx.doi.org/10.1186/s13045-022-01309-0

Ejemplares similares